Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis

INTRODUCTION: Little evidence exists on the safety and efficacy of the rechallenge of immune checkpoint inhibitors (ICIs) after immune-related adverse events (irAEs) in patients with cancer. METHODS: We searched PubMed, Web of Science, Embase, and Cochrane for articles on ICI rechallenge after irAEs...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qing, Zhang, Jianwei, Xu, Lingyi, Yang, Huaxia, Liang, Naixin, Zhang, Li, Zhang, Fengchun, Zhang, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503641/
https://www.ncbi.nlm.nih.gov/pubmed/34646270
http://dx.doi.org/10.3389/fimmu.2021.730320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503641/
https://www.ncbi.nlm.nih.gov/pubmed/34646270
http://dx.doi.org/10.3389/fimmu.2021.730320

Ejemplares similares